Open

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR

To evaluate the safety, optimum drug usage, and anti tumor activity for the drug BDTX-1535.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will be asked to attend onsite visits to obtain the study drug, if disease progression does not occur, you will return every 21 days to receive treatment. These visits will last until all safety assessments are completed. These assessments includes blood work, vital signs, and medication history.

Incentives

Study Drug

In-person visits:
11+

Phone or online visits:
1

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

Have disease progression with prior treatments
Have advanced/metastatic non-small cell lung cancer
Life expectancy of at least 3 months

Not eligible if:

Significant cardiovascular disease
Received other recent antitumor therapy
Major surgery within 4 weeks before first dose of study drug or scheduled for surgery during projected course of the study.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-0821

ClinicalTrials.gov

NCT05256290

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.